Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVETUX: Avelumab + Cetuximab + FOLFOX in mCRC
NCT03174405Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in metastatic colorectal cancer (mCRC), sponsored by AIO-Studien. Primary endpoint: Progression Free Survival Rate at 12 months. Started Jul 2017; status: completed.
02
Drugs
avelumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03174405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174405.